Literature DB >> 7936074

Primary central nervous system malignant non-Hodgkin's lymphomas from HIV-infected and non-infected patients: expression of cellular surface proteins and Epstein-Barr viral markers.

I Auperin1, J Mikolt, E Oksenhendler, J B Thiebaut, M Brunet, B Dupont, F Morinet.   

Abstract

The increased incidence of primary central nervous system malignant non-Hodgkin's lymphomas (PCNSL) in HIV- and non-HIV-infected patients and the demonstration of Epstein-Barr virus (EBV) in these tumours may indicate relationships between PCNSL and EBV. Consequently expression of EBV-induced antigens and cellular markers were studied in 11 HIV-infected and seven non-infected patients by in situ hybridization (ISH) and immunocytochemistry in monoclonal B cell PCNSL. In HIV-infected patients EBV genome was present in 9/11 cases, LMP in 11/11 cases and EBNA2 in 10/11 cases. The expression of adhesion and activation molecules was low or absent. In HIV non-infected patients, EBV genome was present in 5/7 cases, with LMP in 4/7 cases. EBNA2 was never detected. All these lymphomas expressed LFA1beta. Whatever the population, no lytic cycle EBV markers were detected. Compared with other types of EBV lymphomas, our results suggest a different EBV latency state in primary B cell lymphomas of the CNS from HIV-infected or non-infected patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7936074     DOI: 10.1111/j.1365-2990.1994.tb00966.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  5 in total

1.  Epstein-Barr virus EBNA2 blocks Nur77- mediated apoptosis.

Authors:  Jae Myun Lee; Kyoung-Ho Lee; Magdalena Weidner; Barbara A Osborne; S Diane Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-23       Impact factor: 11.205

2.  Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate.

Authors:  Kathryn Lurain; Thomas S Uldrick; Ramya Ramaswami; Mark N Polizzotto; Priscila H Goncalves; Anaida Widell; Seth M Steinberg; Elaine S Jaffe; Stefania Pittaluga; Hao-Wei Wang; Constance M Yuan; Mary Anne Tamula; Staci Martin; Pamela L Wolters; Jomy George; Richard F Little; Robert Yarchoan
Journal:  Blood       Date:  2020-11-05       Impact factor: 22.113

3.  Enhancement of adenovirus vector entry into CD70-positive B-cell Lines by using a bispecific CD70-adenovirus fiber antibody.

Authors:  B F Israel; R J Pickles; D M Segal; R D Gerard; S C Kenney
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Concurrent herpes simplex type 1 necrotizing encephalitis, cytomegalovirus ventriculoencephalitis and cerebral lymphoma in an AIDS patient.

Authors:  C Vital; E Monlun; A Vital; M L Martin-Negrier; V Cales; F Leger; M Longy-Boursier; M Le Bras; B Bloch
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

Review 5.  Primary central nervous system lymphomas--new pathological developments.

Authors:  K A Jellinger; W Paulus
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.